Initial Combination Therapy with Olmesartan/hydrochlorothiazide in Moderate-to-severe Hypertension

A multicentre, randomised, double- blind trial comparison in patients with moderate- to- severe essential hypertension showed that olmesartan medoxomil 20 mg/ hydrochlorothiazide ( HCTZ) 12.5mg ( n = 308) produced greater blood pressure ( BP) reductions than losartan 50 mg/ HCTZ 12.5 mg ( n 305). By week 12, mean sitting diastolic blood pressure ( DBP) reductions ( primary efficacy parameter) were 17.6 and 16.5mmHg ( intention- to- treat ( ITT), P = 0.0708), respectively and 18.2 and 16.7mmHg; ( per protocol ( PP), P = 0.0127).